Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Mural fails to paint a convincing picture for nemvaleukin
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
ALX flunks its gastric test
More bad news for CD47 as response rates in Aspen-06 wane, and the company turns to a subgroup.
Bicara chases Merus
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
